Royalty Pharma (STU:RPD) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:RPD Royalty Pharma PLC STU:RPD
71 GF Score
Price €51.06
GF Value €33.77
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:RPD
71GF Score
Royalty Pharma PLC STU:RPD
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Royalty Pharma (STU:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €51.06 is trading 51.2% above its estimated GF Value™ of €33.77. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for STU:RPD:

  • Interest Received:
  • GF Value™: €33.77 vs. price of €51.06 (51.2% above fair value)
  • GF Score™: 71/100 with 10 warning signs

No single metric tells the full story. See the STU:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
71GF Score

Get the complete analysis for STU:RPD

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.06
Price
€33.77
GF Value